Literature DB >> 3543820

Endocrine manifestations of critical illness in the child.

K Weise, A Zaritsky.   

Abstract

The stress response in humans commonly includes elevations in plasma concentrations of glucocorticoids, catecholamines, glucagon, growth hormone, aldosterone, and renin, resulting in alterations in the metabolism of glucose and other energy substrates, and in increased sodium and water retention. In severe illness, triiodothyronine and sometimes thyroxine are decreased without evidence of clinical hypothyroidism. Antidiuretic hormone may be elevated in bacterial meningitis and other central nervous system disorders, as well as in acute asthma, chronic ventilator therapy, pneumothorax, atelectasis, and postoperatively. Increased ADH concentration can lead to significant hypoosmolality and hyponatremia with adverse effects on the patient. In the setting of severe intracerebral insults, ADH may be inappropriately low, resulting in diabetes insipidus. Insulin concentrations may be inappropriately low for serum glucose concentration, or insulin may have diminished receptor responsiveness in seriously stressed patients. Either situation leads to hyperglycemia. Disturbances in calcium, phosphorus, and magnesium homeostasis may occur relatively frequently in the critically ill patient in response to therapeutic interventions, or illness-induced altered metabolism. It is not always clear when an altered metabolic or hormonal state is an appropriate response to a stress, or represents decompensation of the body's mechanisms for coping with that stress. It is important, however to recognize the common responses of the organism to severe illness, and to monitor for treatable abnormalities which occur.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3543820     DOI: 10.1016/s0031-3955(16)36185-5

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  9 in total

Review 1.  Stress hyperglycemia in pediatric critical illness: the intensive care unit adds to the stress!

Authors:  Vijay Srinivasan
Journal:  J Diabetes Sci Technol       Date:  2012-01-01

2.  Transient hyperglycemia in acute childhood illnesses: to attend or ignore?

Authors:  P Gupta; G Natarajan; K N Agarwal
Journal:  Indian J Pediatr       Date:  1997 Mar-Apr       Impact factor: 1.967

3.  Chronic anemic hypoxemia attenuates glucose-stimulated insulin secretion in fetal sheep.

Authors:  Joshua S Benjamin; Christine B Culpepper; Laura D Brown; Stephanie R Wesolowski; Sonnet S Jonker; Melissa A Davis; Sean W Limesand; Randall B Wilkening; William W Hay; Paul J Rozance
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-01-18       Impact factor: 3.619

4.  Plasma and cerebrospinal fluid arginine vasopressin in patients with and without fever.

Authors:  P M Sharples; J R Seckl; D Human; S L Lightman; D B Dunger
Journal:  Arch Dis Child       Date:  1992-08       Impact factor: 3.791

5.  Glucose replacement to euglycemia causes hypoxia, acidosis, and decreased insulin secretion in fetal sheep with intrauterine growth restriction.

Authors:  Paul J Rozance; Sean W Limesand; James S Barry; Laura D Brown; William W Hay
Journal:  Pediatr Res       Date:  2009-01       Impact factor: 3.756

6.  Critically low hormone and catecholamine concentrations in the primed extracorporeal life support circuit.

Authors:  Michael S D Agus; Tom Jaksic
Journal:  ASAIO J       Date:  2004 Jan-Feb       Impact factor: 2.872

7.  Nutrition Support and Tight Glucose Control in Critically Ill Children: Food for Thought!

Authors:  Vijay Srinivasan
Journal:  Front Pediatr       Date:  2018-11-06       Impact factor: 3.418

Review 8.  Emergency presentation and management of acute severe asthma in children.

Authors:  Knut Øymar; Thomas Halvorsen
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2009-09-04       Impact factor: 2.953

9.  Hyperglycemia in critically ill children.

Authors:  Vinayak Krishnarao Patki; Swati Balasaheb Chougule
Journal:  Indian J Crit Care Med       Date:  2014-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.